Health Literacy Among Caregivers of Children With IgE-mediated Allergy With Risk of Anaphylaxis

NCT ID: NCT04475003

Last Updated: 2020-07-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-30

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Research on health literacy among caregivers of children with IgE-mediated allergy at risk of anaphylaxis (life-threatening allergic reaction). Health literacy is a person's ability to understand health information so that they can maintain or improve their health and quality of life (of themself and children).

The aim of the study is to test the general knowledge of anaphylaxis. Furthermore we test the extent to which caregivers consider themselves able to recognize and to treat anaphylaxis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Health Literacy Anaphylaxis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Teaching

Teaching session about anaphylaxis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* caregivers of children with IgE-mediated allergy with risk of anaphylaxis (adults, grandparents, school caregivers etc.).
* minimum 18 years old.
* signed informed consent

Exclusion Criteria

* none
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Algemeen Ziekenhuis Maria Middelares

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

dr. Jasmine Leus

Kinderarts

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jasmine S Leus

Role: PRINCIPAL_INVESTIGATOR

Algemeen Ziekenhuis Maria Middelares

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Algemeen Ziekenhuis Maria Middelares

Ghent, Oost-Vlaanderen, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jasmine S Leus

Role: CONTACT

+329 246 8200

Josefien L Vandekerckhove

Role: CONTACT

+329 246 8200

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jasmine S Leus

Role: primary

+329 246 8200

Josefien L Vandekerckhove

Role: backup

+329 246 8200

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MMS2020.017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Health Literacy Multi-media Study
NCT02999529 COMPLETED NA
Guideline Adherence for Heart Health
NCT00224848 COMPLETED PHASE2